Anika Therapeutics stock analysis
Anika Therapeutics (AKP) Stock Price & Analysis
AKP Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- CHF 159.60M
- Enterprise Value
- CHF 244.40M
- Total Cash (Recent Filing)
- CHF 44.96M
- Total Debt (Recent Filing)
- CHF 24.57M
- Price to Earnings (P/E)
- ―
- Beta
- 0.98
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- 0.16
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Multi-channel Revenue Growth
Growth across both commercial and OEM channels indicates broader demand rather than reliance on a single product route. Record commercial revenue, strong international performance, and continued OEM execution can support a more diversified and durable revenue base over the next several quarters.
Long-term Commercial Partnership
The extended Boehringer relationship improves commercial visibility through contractual minimum purchases, higher transfer pricing, and royalties on end-market sales. The expected $8 million of payments also supports near-term funding while strengthening the economics of an established channel.
Operational Improvement And Capacity
Improved gross margin, manufacturing execution, and validated process capacity suggest that operational gains are becoming embedded in the business. Higher production capability and safety-stock investment should help Anika serve demand growth while supporting better profitability over time.
Bears Say
Profitability Remains Incomplete
Although losses have narrowed and adjusted metrics improved, negative GAAP operating profit and net income show that the business has not yet established consistent earnings power. Continued investment and revenue growth must translate into durable operating leverage before returns become attractive.
HYALOFAST Regulatory Setback
The FDA decision removes expected U.S. HYALOFAST sales from the forward outlook and may require additional clinical evidence before approval. This delays a potential product contribution, increases development uncertainty, and limits the near-term value of that pipeline asset.
Pricing And Growth Pressure
Expected U.S. osteoarthritis pricing declines could pressure revenue quality and margins in a core market. Combined with a reduced commercial growth outlook and only flat-to-5% total growth guidance for 2027, this limits near-term expansion while the company invests in new areas.
Anika Therapeutics News
AKP FAQ
What is Anika Therapeutics’s market cap?
When is Anika Therapeutics’s upcoming earnings report date?
How were Anika Therapeutics’s earnings last quarter?
Is Anika Therapeutics overvalued?
Does Anika Therapeutics pay dividends?
What is Anika Therapeutics’s EPS estimate?
How many shares outstanding does Anika Therapeutics have?
What happened to Anika Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Anika Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Anika Therapeutics Stock Smart Score
Company Description
Anika Therapeutics
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- Stephen D. Griffin
- Employees
- 235
- Website
- www.anika.com
- Address
- 32 Wiggins Avenue, Bedford, MA, 01730, US
Anika Therapeutics (AKP) Earnings & Revenues
AKP Company Deck
AKP Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, with 10% third-quarter revenue growth, record commercial revenue, strong Integrity performance, improved year-over-year gross margin and profitability, higher 2026 guidance, a favorable long-term Boehringer agreement, and meaningful manufacturing and CINGAL milestones. Offsetting concerns included softer U.S. elective surgery activity, a lower commercial growth outlook, expected 2027 U.S. pricing declines, lower year-to-date operating cash flow, and the HYALOFAST PMA being deemed not approvable. Highlights significantly outweighed the lowlights.
View all CH:AKP earnings summaries